HPSE and synovial sarcoma: Heparanase has been shown to be an actionable target in various sarcoma models [28, 29] and we have reported that both heparin derivatives and small molecule heparanase inhibitors produce a remarkable impact on SS cell malignant behavior in vitro and in vivo [37–39, 60].